Search results
Showing 901 to 950 of 2048 results for work
Venous thromboembolism (recurrent) - idraparinux sodium [ID395]
Discontinued Reference number: GID-TAG384
Discontinued Reference number: GID-TAG381
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Suspected neurological conditions: recognition and referral (QS198)
This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS198Show all sections
Sections for QS198
- Quality statements
- Quality statement 1: Headaches and 'red flag' symptoms in children
- Quality statement 2: Head size and shape in children
- Quality statement 3: Suspected dystonia in adults
- Quality statement 4: Hallpike manoeuvre for adults
- Quality statement 5: Functional neurological disorders in adults
- Quality statement 6: Individualised care for adults
- About this quality standard
Discontinued Reference number: GID-TAG432
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Percutaneous interlaminar endoscopic lumbar discectomy for sciatica (HTG411)
Evidence-based recommendations on percutaneous interlaminar endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.
View recommendations for HTG411Show all sections
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Discontinued Reference number: GID-TA10961
Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.
View recommendations for HTG757Show all sections
Discontinued Reference number: GID-TA10843
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Discontinued Reference number: GID-TA11018
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
Discontinued Reference number: GID-TAG422
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
In development Reference number: GID-HTE10084 Expected publication date: 21 October 2026
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041
Discontinued Reference number: GID-TA10525
Discontinued Reference number: GID-TA10937
Discontinued Reference number: GID-TA10929
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Discontinued Reference number: GID-TA10863
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Discontinued Reference number: GID-TA10208
Discontinued Reference number: GID-TA10707
Discontinued Reference number: GID-TA10144
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
Discontinued Reference number: GID-HST10004
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Discontinued Reference number: GID-TA10750
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Discontinued Reference number: GID-TA10617
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Discontinued Reference number: GID-TA10728
Discontinued Reference number: GID-TA10880
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Discontinued Reference number: GID-TA10848
Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]
Discontinued Reference number: GID-TA10927
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
Discontinued Reference number: GID-TA10211
Discontinued Reference number: GID-TA11258
Capecitabine for the treatment of advanced pancreatic cancer [ID127]
Discontinued Reference number: GID-TA11239
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
Discontinued Reference number: GID-TA10768
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued Reference number: GID-TA11261
Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]
Discontinued Reference number: GID-TA11173
Discontinued Reference number: GID-TA10474
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Discontinued Reference number: GID-TA10851
Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]
Discontinued Reference number: GID-TA11240
Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088
Discontinued Reference number: GID-TA11702
Terevalefim for treating delayed graft function after kidney transplant [ID1490]
Discontinued Reference number: GID-TA11098
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]
Discontinued Reference number: GID-TA10203
Discontinued Reference number: GID-TA10767
Discontinued Reference number: GID-TA10859
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued Reference number: GID-TA10394